TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05464862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Popliteal Plexus Block with 10 ml
Description: Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Popliteal Plexus Block with 20 ml
Description: Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Popliteal Plexus Block with 30 ml
Description: Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic Nerve Block
Description: Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
Study: NCT05837052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serplulimab plus chemotherapy as conversion treatment
Description: Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.
Study: NCT04350190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablet
Description: The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
Study: NCT02503176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809 ophthalmic solution
Study: NCT04903964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family-centered nutrition education
Description: There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family-centered nutrition education
Description: There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
Study: NCT04969133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
Study: NCT05902546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity aerobic exercise
Description: Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
Study: NCT04726293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango
Description: Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: control beverage 1 cup, twice a day for 4 weeks
Study: NCT05189158

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hypercapnic hyperoxic ventilatory response
Description: The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hypercapnic hyperoxic ventilatory response
Description: The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hypoxic eucapnic ventilatory response
Description: The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hypoxic eucapnic ventilatory response
Description: The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
Study: NCT05403749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dose 1 IBI302
Description: After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dose 2 IBI302
Description: After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
Study: NCT06273306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMIDOC
Description: Patient´s Mobile App for recording clinical data
Study: NCT05834764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
Study: NCT05341505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Intervention
Description: We will administer a cognitive-behavioral treatment targeting emotion dysregulation, including mindfulness skills and other cognitive and behavioral emotion regulation skills.
Study: NCT05998954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block
Description: Fifteen ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. Fifteen ml of 0.375% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprainguinal fascia iliaca block
Description: Thirty ml of 0.375% ropivacaine will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
Study: NCT06260579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise/physical activity
Description: personalized exercise training and physical activity program
Study: NCT05593159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dentin Conditioning
Description: After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RM-GIC
Description: RM-GIC (Fuji II LC) will be applied in \<2mm incremental layers afterword light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-step adhesive
Description: A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).
Study: NCT05509218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-delivered personalized feedback
Description: Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-delivered personalized feedback
Description: Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
Study: NCT05102149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-201
Description: PB-201: 100 mg each time, orally in the morning and evening respectively;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin: 50 mg each time, orally in the morning and evening respectively;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-201 matched placebo
Description: PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PB-201 matched placebo
Description: PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vildagliptin matched placebo
Description: One tablet each time, orally in the morning and evening respectively;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin matched placebo
Description: One tablet each time, orally in the morning and evening respectively;
Study: NCT05154266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking it Further
Description: This programme is offered to individuals who have already completed a Mindfulness-Based Cognitive Therapy (MBCT) or Mindfulness-Based Stress Reduction Programme (MBSR). In this programme, participants explore weekly themes (i.e. 'Responding not reacting' and 'Taking care of ourselves, taking care of others'). These themes reinforce the learning from the eight-week MBCT/MBSR courses whilst also providing new learning opportunities. The programme makes some of the dimensions that are implicit in MBCT/MBSR more explicit; for example, the cultivation of attitudes of mindfulness (such as equanimity, joy, and kindness). These attitudes of mindfulness require a foundational mindfulness practice and thus this is an additive learning theme from traditional MBCT/MBSR programmes.
Study: NCT05644379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Injection
Description: Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 80mg, po, orally once daily
Study: NCT06155760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 10mg of prednisolone plus standard medical therapy for 60 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical therapy
Description: IV Albumin, Diuretics, Multi vitamins as per clinicians decision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical therapy
Description: IV Albumin, Diuretics, Multi vitamins as per clinicians decision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06522581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline Sodium
Description: one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citicoline Sodium
Description: one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
Study: NCT06491628

Intervention type: BEHAVIORAL
Intervention: Avoiding the risk factors
Description: Exercise, Salt and lipid reduction in diet, smoking cessation

Intervention type: BEHAVIORAL
Intervention: Avoiding the risk factors
Description: Exercise, Salt and lipid reduction in diet, smoking cessation

Intervention type: BEHAVIORAL
Intervention: Avoiding the risk factors
Description: Exercise, Salt and lipid reduction in diet, smoking cessation

Intervention type: BEHAVIORAL
Intervention: Avoiding the risk factors
Description: Exercise, Salt and lipid reduction in diet, smoking cessation

Intervention type: BEHAVIORAL
Intervention: Avoiding the risk factors
Description: Exercise, Salt and lipid reduction in diet, smoking cessation
Study: NCT06004141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laguna Health
Description: Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
Study: NCT05372341

Intervention type: OTHER
Intervention: descriptive
Description: posotcovid patients will be elective surgery postoperative outcomes
Study: NCT05593159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N
Description: The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
Study: NCT01511835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inositol + folic acid
Description: 2000 mg of inositol+200mcg of folic acid; 2 per diem

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inositol + folic acid
Description: 600 mg of inositol + 200mcg of folic acid; 2 cp per diem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid 400mcg; 1 cp/die
Study: NCT06015802

Intervention type: OTHER
Intervention: diagnosed and treated reasonably according to the clinical guidelines and clinical pathways
Description: The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
Study: NCT06490419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolipolysis
Description: Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, with physiological nutrient content: carbohydrates-50%, proteins-20%, fats-30% and fiber daily consumption of 30 - 40 g in dry form (grain and vegetables). Calorie distribution: breakfast-40%, lunch-40%, dinner-20%. Behavioral therapy to correct eating disorders: diary of food and lifestyle, motivational phone calls every week~Electrolipolysis:~the participants will receive electrolipolysis applied to abdomen, thigh and gluteal regions, 3 sessions/week, for 3 months, 60 minutes/session; 30 minutes on the abdomen and thigh and 30 minutes on gluteal region. the device will be set to cause a contraction for 4 seconds followed by a relaxation for 4 seconds with a pulse width of 400 microseconds and a frequency of 20 pulses per minute.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound cavitation
Description: Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, as in the electrolipolysis group.~ultrasound cavitation (UC): The participants will be treated by UC on the abdomen for 30 minutes, two sessions per week for 3 months. From standing position, the abdominal area of each patient will be divided transversally into 3 parts; part I: from the xiphoid process to 3 cm above the umbilicus, part II: from 3cm above the umbilicus to 2 cm below the umbilicus and part III: from 2 cm below the umbilicus to the pubic bone. Vertically, each part will be divided into right and left segments in relation to the linea alba, forming a total of 6 abdominal segments.~The program of cavitation; frequency (40 kHz) will be chosen, the time will be adjusted at 30 minutes. The cavitational head will be, then, moved very slowly on each abdominal segment in a small circular movement for 5 minutes.
Study: NCT05349578

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: swab RUT
Description: rapid urease test using swab instead of biopsied tissue

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: swab RUT
Description: rapid urease test using swab instead of biopsied tissue
Study: NCT05593159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N
Description: The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentin roughness
Description: Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival retentive groove preparation
Description: Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
Study: NCT06554418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communities Care
Description: Communities Care is a violence prevention program targeting social norms and behavioral change
Study: NCT04958382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medium/long chain fat emulsion injection (C8-24Ve)
Description: at the infusion rate of 25-30 mL/h
Study: NCT06446726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will undergo two cycles of immunotherapy, each cycle lasting 21 days. Day 3 and Day 24: Tislelizumab, fixed dose of 200 mg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Patients will undergo two cycles of low-dose radiotherapy. Day 1/2 and Day 22/23: Low-dose radiotherapy (8 Gy/4f)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Nab-paclitaxel 260 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Cisplatin 75 mg/m2.
Study: NCT04820361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis sativa L., folium cum flore
Description: Muscle Relaxation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Muscle Relaxation
Study: NCT05143658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLS versus LP
Description: Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLS versus LP
Description: Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
Study: NCT05817097

Intervention type: DRUG
Intervention: Dipeptidyl peptidase-4 inhibitor
Description: The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.